26 results
Thumbnail

D1.496 - Variation in platelet-activating factor levels among patients with chronic spontaneous urticaria

Thumbnail

D1.507 - Biomarkers of T2-airway inflammation in patients with asthma and COPD overlap

Thumbnail

D1.498 - Altered B Cell Dynamics in Childhood-Onset Systemic Lupus Erythematosus: Insights from Disease States and Rituximab Treatment

Thumbnail

D1.504 - Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2: Clinical Characteristics and Outcomes in a series of pediatric cases

Thumbnail

D1.506 - Mast cell activation and type 2 inflammation in heart failure with preserved ejection fraction: a pilot cross-sectional study

Thumbnail

D1.508 - Assessment of automated serum sIgG testing for key bacterial pathogens in Cystic Fibrosis

Thumbnail

D1.510 - Fecal Calprotectin as a Marker for Differentiating Children with Atopic Dermatitis With and Without Food Allergy

Thumbnail

D1.511 - Hereditary alpha-tryptasemia in chronic spontaneous urticaria: prevalence and clinical impact

Thumbnail

D1.513 - Reduced Expression of PDCD4 on CD14+ Monocytes Correlates with Inflammatory Severity in Neonatal Sepsis: A Pilot Study

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to

Thumbnail

D2.503 - LP-003 Injection for the treatment of H1 Antihistamine-Inadequately Controlled Chronic Spontaneous Urticaria (CSU): A Multicenter, Randomized, Double-Blind, Controlled Phase Ⅱ Study

Thumbnail

D3.323 - SBK007: A Novel Oral H1 Antihistamine with Rapid Onset (30min): Preclinical Pharmacodynamics in Acute Urticaria

Thumbnail

D3.324 - Hereditary Angioedema Attack Frequency and Severity According to Individuals Taking Berotralstat for Long-Term Prophylaxis

Thumbnail

D3.325 - Immediate-type allergic reactions associated with thiuram mix sensitization in an adolescent with atopic dermatitis: a case report